Moon Eun-Sang – CEO, SillaJen – South Korea
SillaJen’s CEO shares his passion for his companies oncolytic vaccinia virus, and its potential to revolutionize the treatment of solid tumor cancers, even arguing that it may eventually constitute ‘a…
SillaJen, Inc. is a privately-held biotechnology company focusing on engineering and developing best-in-class oncolytic immunotherapeutics. SillaJen has Korean offices in Busan (R&D), at Pusan National University (PNU), and in Seoul (finance, management & legal). SillaJen also has Clinical R&D, regulatory affairs and CMC capabilities in San Francisco, California, one of the world’s leading biotechnology centers and the “birthplace” of the biotech industry. SillaJen products are engineered from vaccinia which has unique attributes as an oncolytic immunotherapy.
Contact Details
Busan Office
Seoul Office
San Francisco Office
SillaJen’s CEO shares his passion for his companies oncolytic vaccinia virus, and its potential to revolutionize the treatment of solid tumor cancers, even arguing that it may eventually constitute ‘a…
South Korea has a short history of participating in global clinical trials, but now the country is seeing exponential growth in this area. What has changed in recent years leading…
What are the main milestones and achievements of Daewoong’s pharmaceutical business over its decades of evolution? Daewoong was first established in 1945 as Chosun Liver-oil Pharmaceutical Industry Co., Ltd. The…
Could you provide our international readers with a profile of Bioneer as it stands today? Bioneer, having a strong basis of technology and experiences in molecular biology since 1992, we…
Although Chungcheongbuk-do is a small province in terms of territory and population, it has gained increasing importance in Korea’s economy. What are the main drivers of this growing economic progression?…
How did you first get involved in clinical trials and what inspired you to create your own CRO, ADM Korea? When I was working at CJ, the company was starting…
You have recently taken over the position as head of AstraZeneca in South Korea, after several years working in China. What view did you have of the Korean pharmaceutical sector…
You are one of the foreign multinational directors with most time in the Korean pharmaceutical industry, since 2003. What is your assessment of the direction the market has taken in…
What is KHIDI’s role in supporting the development of the Korean health industry? KHIDI performs three major roles in supporting the Korean health industry, which includes pharmaceuticals, medical devices, cosmetics,…
Previous to your current position as President of Pfizer Korea since 2004, you had been in the country between 1989 and 1993 as sales and marketing director. How different are…
Please introduce Handok Pharmaceuticals to our readers, and in particular how it has evolved through partnerships with different multinational companies throughout its history. Handok has developed in a very unique…
Korea had a late start, but is now one of the global hot spots for clinical trials. How would you sum up and explain this quick evolution? Clinical trials in…
You have been in South Korea for several months, following some time as Merck’s President in Pakistan. In your opinion, what do you find as the most interesting aspects of…
See our Cookie Privacy Policy Here
